Benazepril Hydrochloride Loaded Niosomal Formulation for Oral Delivery: Formulation and Characterization

Radhi, Ameera A

doi:10.22159/ijap.2018v10i5.27564

Cited by 9 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The composition of the niosomal bilayer and the amount and type of the charge-inducing agents affected the ZP of niosomes [51]. The ZP of niosomes ranged from 25.40 ± 0.52 to 50.2 ± 3.74, which is enough to ensure repulsion between the vesicles and prevent aggregation, resulting in stable niosomes [53].…”

Section: Characterization Of Aa and Caff Loaded Niosomesmentioning

confidence: 99%

Development and Evaluation of an Innovative Approach Using Niosomes Based Polymeric Microneedles to Deliver Dual Antioxidant Drugs

et al. 2023

View full text Add to dashboard Cite

Ascorbic acid (AA) and caffeine (CAFF) work to protect cells from ultraviolet (UV) radiation and slow down the photoaging process of the skin. However, cosmetic application of AA and CAFF is limited due to poor penetration across the skin and rapid oxidation of AA. The aim of this study was to design and evaluate the dermal delivery of dual antioxidants utilizing microneedles (MNs) loaded with AA and CAFF niosomes. The niosomal nanovesicles were prepared using the thin film method and had particle sizes ranging from 130.6–411.2 nm and a negative Zeta potential of around −35 mV. The niosomal formulation was then combined with polyvinylpyrrolidone (PVP) and polyethylene glycol 400 (PEG 400) to create an aqueous polymer solution. The best skin deposition of AA and CAFF was achieved with the formulation containing 5% PEG 400 (M3) and PVP. Furthermore, the role of AA and CAFF as antioxidants in preventing cancer formation has been well-established. Here we validated the antioxidant properties of ascorbic acid (AA) and caffeine (CAFF) in a novel niosomal formulation referred to as M3 by testing its ability to prevent H2O2-indued cell damage and apoptosis in MCF-7 breast cancer cells. Results showed that M3 was able to shield MCF-7 cells from H2O2 induced damage at concentrations below 2.1 µg/mL for AA and 1.05 µg/mL for CAFF, and also exhibited anticancer effects at higher concentrations of 210 µg/mL for AA and 105 µg/mL. The formulations were stable for two months at room temperature in terms of moisture and drug content. The use of MNs and niosomal carriers could be a promising approach for dermal delivery of hydrophilic drugs like AA and CAFF.

show abstract

Section: Characterization Of Aa and Caff Loaded Niosomesmentioning

confidence: 99%

Development and Evaluation of an Innovative Approach Using Niosomes Based Polymeric Microneedles to Deliver Dual Antioxidant Drugs

et al. 2023

View full text Add to dashboard Cite

show abstract

“…F2 does not contain DCP, while F6 contains 0.01 M DCP (Table 1). Span ® 60 produces a larger size niosome due to the longer alkyl group that produces a wider bilayer, resulting in a larger vesicle [21].…”

Section: Niosome Size Zeta Potential and Polydispersity Index (Pdi)mentioning

confidence: 99%

Formulation and In Vivo Pain Assessment of a Novel Niosomal Lidocaine and Prilocaine in an Emulsion Gel (Emulgel) of Semisolid Palm Oil Base for Topical Drug Delivery

Shabery

Widodo

Chik

2023

Gels

View full text Add to dashboard Cite

This study aimed to formulate semisolid niosomal encapsulated lidocaine and prilocaine using the patented palm oil base Hamin-C® for further characterization and in vivo pain assessment. Seven formulations were initially studied with various chemical compositions. A thin-layer film hydration method was used to produce niosome using a mixture of surfactant (Span® 40 or Span® 60) and cholesterol (CHOL) at a 1:1 ratio, with/without a charge-inducing agent (diacetyl phosphate) (DCP) and with/without labrasol®. Niosome F1 formulation had been identified as the highest %EE achieved, at 53.74 and 55.63% for prilocaine and lidocaine, respectively. Furthermore, NIO-HAMIN F1 emulgel indicated the best formulation with higher permeability of prilocaine and lidocaine compared to the rest of the formulations. The reformulation of optimization of NIO-HAMIN F1 emulgel using a cold process to NIO-HAMIN F1-C emulgel to improve the viscosity resulted in higher diffusion of prilocaine and lidocaine by 5.71 and 33.38%, respectively. In vivo pain perception studies by verbal rating score (VRS) and visual analogue score (VAS) on healthy subjects show a comparable local anesthetic effect between NIO-HAMIN F1-C emulgel and EMLA® cream.

show abstract

Niosomes-Based Drug Delivery in Targeting the Brain Tumors Via Nasal Delivery

Gharbavi

Parvanian

Leilan

et al. 2023

Nasal Drug Delivery

View full text Add to dashboard Cite

Benazepril Hydrochloride Loaded Niosomal Formulation for Oral Delivery: Formulation and Characterization

Cited by 9 publications

References 16 publications

Development and Evaluation of an Innovative Approach Using Niosomes Based Polymeric Microneedles to Deliver Dual Antioxidant Drugs

Development and Evaluation of an Innovative Approach Using Niosomes Based Polymeric Microneedles to Deliver Dual Antioxidant Drugs

Formulation and In Vivo Pain Assessment of a Novel Niosomal Lidocaine and Prilocaine in an Emulsion Gel (Emulgel) of Semisolid Palm Oil Base for Topical Drug Delivery

Niosomes-Based Drug Delivery in Targeting the Brain Tumors Via Nasal Delivery

Contact Info

Product

Resources

About